Kotak Strategic Situations India Fund II, managed by Kotak Alternate Asset Managers, has announced a significant investment of ₹940 crore in Neuberg Diagnostics to support the company’s expansion strategy.

The investment is expected to play a crucial role in bolstering Neuberg’s inorganic growth plans, the company said in a statement. Neuberg, founded by industry veteran GSK Velu, has emerged as a major player in India’s diagnostic sector. The company operates an extensive network of over 10,000 touchpoints and 250 labs spread across 250 cities. It claims market leadership in Gujarat and Karnataka.

In addition to its diagnostic services, Neuberg is the second-largest genomics player in India, particularly noted for its expertise in newborn screening and reproductive genomics testing.

Rahul Shah, Partner at Kotak Alt, said the investment reflects confidence in Neuberg’s growth potential. He highlighted that the funds would help the company scale and prepare for an upcoming IPO.

GSK Velu, Founder and MD of Neuberg, said the investment would enhance the company’s capabilities in personalised medicine, integrated diagnostics, and support inorganic growth across India.

“As we prepare for an IPO, we remain committed to making high-quality diagnostics accessible to all,” he added.